The saturated medium-chain fatty-acid lauric acid (LA) has been associated to certain health-promoting benefits of coconut oil intake, including the improvement of the quality of life in breast cancer patients during chemotherapy. As it concerns the potential to hamper tumor growth, LA was shown to elicit inhibitory effects only in colon cancer cells. Here, we provide novel insights regarding the molecular mechanisms through which LA triggers antiproliferative and pro-apoptotic effects in both breast and endometrial cancer cells. In particular, our results demonstrate that LA increases reactive oxygen species levels, stimulates the phosphorylation of EGFR, ERK and c-Jun and induces the expression of c-fos. In addition, our data evidence that LA via the Rho-associated kinase-mediated pathway promotes stress fiber formation, which exerts a main role in the morphological changes associated with apoptotic cell death. Next, we found that the increase of p21Cip1/WAF1 expression, which occurs upon LA exposure in a p53-independent manner, is involved in the apoptotic effects prompted by LA in both breast and endometrial cancer cells. Collectively, our findings may pave the way to better understand the anticancer action of LA, although additional studies are warranted to further corroborate its usefulness in more comprehensive therapeutic approaches.
Fatty acids are acyclic carboxylic acids with aliphatic tails of different lengths. Based on their carbon atom chain length, fatty acids are classified into the following three groups: short-chain fatty acids with <6 carbon atoms, medium-chain fatty acids (MCFA) and long-chain fatty acids that contain 6–12 carbons and >12 carbons, respectively.1 Fatty acids are major components of triacylglycerols, phospholipids and other complex lipids, therefore representing main contributors to dietary fat in humans.2 Plant oils like palm, coconut and olive oils, nuts, seeds and seed oils, cocoa butter and animal-derived fats as lard, tallow and butter, are rich of fatty acids that are important components of cell membranes and essential sources of energy.2 Previous studies have demonstrated that fatty acids are also involved in diverse transduction pathways, in gene transcription and relevant biological events as cell metabolism, inflammation, apoptosis and production of bioactive lipid mediators, thus contributing to multiple patho-physiological responses.2,
Lauric acid (LA), which is a saturated MCFA with 12 carbon atoms and the primary fatty acid of coconut oil, has been associated with certain health benefits of coconut oil intake.8,
Here, we show for the first time that LA elicits antiproliferative and pro-apoptotic effects in breast and endometrial cancer cells promoting the generation of reactive oxygen species (ROS), the activation of transduction pathways and gene expression changes. In particular, the upregulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 upon LA exposure was found to be required for its anticancer properties. Our findings shed new light on the molecular mechanisms through which LA induces antiproliferative and pro-apoptotic responses in both breast and endometrial cancer cells toward its usefulness in more comprehensive therapeutic approaches.
LA inhibits cancer cell viability
On the basis of previous findings showing that MCFAs may elicit apoptosis in certain cancer cells17,20 and considering that in our recent investigation LA exerted antiproliferative activity in diverse types of tumor cells,21 we began the present study evaluating whether LA (Figure 1a) and a further MCFA namely capric acid (CA) (Figure 1b) may affect the viability of SkBr3 breast and Ishikawa endometrial cancer cells, which were used as model system. Only LA inhibited the viability of both cancer cell types (Figures 1c and d) without altering the growth of MCF-10A normal breast epithelial cells (Figure 1e), thus suggesting its specific potential to trigger antiproliferative effects in malignant cells.
LA triggers ROS generation and EGFR, ERK and c-Jun phosphorylation
To evaluate the molecular mechanisms involved in the ability of LA to lower cancer cell viability, we ascertained that LA triggers the phosphorylation of EGFR, ERK and c-Jun in both SkBr3 and Ishikawa cells (Figures 2a and b). These responses were no longer observed in the presence of the EGFR inhibitor (AG) (Figures 2c and d), whereas ERK activation by LA was abolished using the MEK inhibitor (PD) and the Rho-associated kinase (ROCK) inhibitor (Y) but it still persisted using the JNK inhibitor (SP) (Figures 2c and d). The phosphorylation of c-Jun by LA was prevented in the presence of PD or SP, but not using the ROCK inhibitor Y (Figures 2c and d). Reminiscing previous data on the ability of LA to induce ROS levels in colon cancer cells,17 we found that LA triggers ROS generation in our model system, yet this response was no longer evident using the ROS scavenger N-acetyl-l-cysteine (NAC, Figure 3a). Thereafter, we established that the phosphorylation of EGFR, ERK and c-Jun upon LA exposure is strictly dependent on ROS generation, as ascertained using NAC in both cell types (Figures 3b and c).
LA induces gene expression changes
Then, we assessed the expression levels of well-known cell cycle regulators as the member of the AP1 transcription factor complex namely c-fos, the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21Cip1/WAF1. In both SkBr3 and Ishikawa cells, LA upregulated the mRNA expression of c-fos and p21Cip1/WAF1, without altering the levels of p53 (Figures 4a and b). In addition, LA transactivated the AP1-luc responsive collagenase promoter construct that was transiently transfected in SkBr3 and Ishikawa cells and stimulated the transcriptional activity of reporter plasmids containing the c-fos and p21Cip1/WAF1 promoter sequences (Figures 4c and d). According to the results obtained in real-time PCR, LA did not modify the p53 protein levels, whereas it increased c-fos and p21Cip1/WAF1 protein expression in both cell types (Figures 4e and f). We next ascertained that the ROS scavenger NAC, the EGFR inhibitor AG, the MEK inhibitor PD and the ROCK inhibitor Y prevent c-fos induction by LA (Figures 5a and b). Likewise, these compounds together with the JNK inhibitor SP repressed the increase of p21Cip1/WAF1 protein levels elicited by LA (Figures 5a and b). As the upregulation of p21Cip1/WAF1 protein levels was no longer evident transfecting a dominant-negative form of c-fos (DN/c-fos) in both SkBr3 and Ishikawa cells (Figures 5c and d), we ascertained by chromatin immunoprecipitation assay that LA induces the recruitment of c-fos to the AP1 site located within the p21Cip1/WAF1 promoter sequence (Figure 5e). Overall, these data indicate that c-fos-AP1 transduction signaling is involved in the upregulation of p21Cip1/WAF1 induced by LA.
LA promotes stress fiber formation and apoptosis in cancer cells
Rho GTPases and their effectors as the Rho-associated protein kinase (ROCK) are key regulators of the cytoskeleton reorganization and the generation of the contractile force required for stress fiber formation.22 In line with the aforementioned findings regarding the capability of the ROCK inhibitor to prevent LA-induced responses, in both SkBr3 and Ishikawa cells LA promoted the formation of stress fibers in a ROCK-dependent manner as this effect was abrogated in the presence of its inhibitor (Figures 6a-f) that alone did not show any effects (data not shown). Then, we assessed that LA increases the percentage of SkBr3 (Figures 7a–c) and Ishikawa (Figures 7d-f) TdT-mediated dUTP nick-end-labeling (TUNEL)-positive cells, however this effect was prevented in the presence of the ROS scavenger NAC (Figure 7). In addition, the apoptotic effects induced by LA were blocked in the presence of the p21Cip1/WAF1 inhibitor UC2288 (Figure 7), suggesting that p21Cip1/WAF1is involved in the pro-apoptotic activity exerted by LA in breast and endometrial cancer cells.
The present study provides novel evidence regarding the molecular mechanisms through which LA elicits antiproliferative and pro-apoptotic effects in breast and endometrial cancer cells. In particular, we have ascertained that ROS generation induced by LA triggers the activation of the EGFR/ERK/AP1 transduction pathway, leading to the upregulation of p21Cip/WAF1 in a p53-independent manner.
Fatty acids are structural components of cellular membranes either alone or together with other molecules as phospholipids and triacylglycerides.23 In addition, fatty-acid oxidation occurring at the mitochondrial level plays a pivotal role in maintaining energy homeostasis during catabolic states.24 Nevertheless, fatty acids are currently no longer considered as mere membrane structure regulators or energy sources as they also influence diverse transduction signaling and cellular functions.2,
Actin stress fibers have a pivotal role in many cellular functions, including cell adhesion, mobility, contraction and morphogenesis.37 Stress fibers are also required for membrane blebbing, nuclear disintegration and apoptosis.38,
The cyclin-dependent kinase inhibitor p21Cip1/WAF1 has an essential role in the cell cycle arrest, the transcriptional regulation, the inhibition of DNA replication, the DNA repair, the stress-induced premature senescence and the modulation of apoptosis.45,
Overall, the present results provide novel insights into the potential of LA to activate the EGFR/ERK/AP1/p21Cip1/WAF1 transduction signaling toward antiproliferative and pro-apoptotic responses in tumor cells. Nevertheless, further experimental evidence are warranted to better define the action of LA alone or in the context of coconut oil consumption on tumor development as claimed by a current newsworthy debate.
Materials and methods
LA, CA, NAC, Y-27632 (Y) and 2′,7′-dichlorofluorescin diacetate (DCFDA) were purchased from Sigma-Aldrich (Milan, Italy). Tyrphostin AG1478 (AG), PD98059 (PD), SP 600125 (SP) and UC2288 were obtained from Calbiochem (DBA, Milan, Italy). All compounds were dissolved in dimethyl sulfoxide except LA, CA, NAC and Y-27632 (Y), which were solubilized in water.
SkBr3 breast cancer cells were obtained by ATCC, used <6 months after resuscitation and maintained in RPMI 1640 without phenol red supplemented with 10% FBS and 100 mg/ml penicillin/streptomycin (Life Technologies, Milan, Italy). Ishikawa endometrial cancer cells were obtained by D Picard (University of Geneva) and maintained in MEM supplemented with 10% FBS, 100 μg/ml penicillin/streptomycin, 2 mM L-glutamine and 1% Non-Essential Amino Acids Solution Cells (Life Technologies). Cells were switched to medium without serum the day before immunoblots and reverse transcription-PCR experiments.
Cell viability assay
Cell viability was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, which is based on the conversion of MTT to MTT formazan by mitochondrial enzyme. Cells were seeded in quadruplicate in 96-well plates in regular growth medium and grown until 70–80% confluence. Cells were washed once they had attached and then treated with increasing concentrations of each compound for 48 h in regular medium supplemented with 1% FBS. Relative cell viability was determined by MTT assay according to the manufacturer’s protocol (Sigma-Aldrich). Mean absorbance of cells receiving vehicle (−) was set as onefold induction upon which the mean absorbance of treatments was calculated.
Plasmids, transfections and gene reporter assays
The luciferase reporter plasmid for c-fos encoding a 2.2-kb 5´ upstream fragment of human c-fos was a gift from Dr. K Nose (Hatanodai, Shinagawa-ku, Tokyo). The luciferase reporter plasmid for AP1 responsive collagen promoter was a kind gift from H Van Dam (Department of Molecular Cell Biology, Leiden University, Leiden, Netherlands). The human p21Cip1/WAF1 promoter-luciferase reporter was kindly provided by Dr T Sakai (Kyoto Prefectural University of Medicine, Kyoto, Japan). The Renilla luciferase expression vector pRL-TK (Promega, Milan, Italy) was used as internal transfection control in luciferase assays. Cells (1×105) were plated into 24-well plates with regular growth medium/well the day before transfection. Cell medium was replaced on the day of transfection with serum-free medium and transfection was performed using X-tremeGENE 9 DNA Transfection Reagent (Sigma-Aldrich) and a mixture containing 0.5 μg of each reporter plasmid and 5 ng of pRL-TK. After 6 h, treatments were added and cells were incubated for 18 h. Luciferase activity was measured using the Dual Luciferase Kit (Promega) according to the manufacturer’s recommendations. Firefly luciferase activity was normalized to the internal transfection control provided by the Renilla luciferase activity. Normalized relative light unit values obtained from cells treated with vehicle were set as onefold induction upon which the activity induced by treatments was calculated.
The plasmid DN/c-fos, which encodes a c-fos mutant that heterodimerizes with c-fos dimerization partners but does not allow DNA biding,55 was a kind gift from Dr C Vinson (NIH, Bethesda, MD, USA). Cells were plated onto 10-cm dishes and prior to treatments cells were transfected for 24 h using X-tremeGENE 9 DNA Transfection Reagent (Sigma-Aldrich) with a control vector and the plasmid DN/c-fos.
Gene expression studies
Total RNA was extracted and cDNA was synthesized by reverse transcription as previously described.56 The expression of selected genes was quantified by real-time PCR using Step One (TM) sequence detection system (Applied Biosystems Inc, Milan, Italy). Gene-specific primers were designed using Primer Express version 2.0 software (Applied Biosystems). For c-fos, p53, p21Cip1/WAF1 (p21) and the ribosomal protein 18S, which was used as a control gene to obtain normalized values, the primers were: 5′- CGAGCCCTTTGATGACTTCCT-3′ (c-fos forward), 5′- GGAGCGGGCTGTCTCAGA-3′ (c-fos reverse); 5′- GCTTCATGCCAGCTACTTC-3′ (p53 forward), 5′- GGCATTCTGGGAGCTTCATCT-3′ (p53 reverse); 5′- GCTTCATGCCAGCTACTTCC-3′ (p21 forward) and 5′- CTGTGCTCACTTCAGGGTCA-3′ (p21 reverse); 5′- GGCGTCCCCCAACTTCTTA-3′ (18S forward) and 5′- GGGCATCACAGACCTGTTATT-3′ (18S reverse), respectively. Assays were performed in triplicate and the results were normalized for 18S expression and then calculated as fold induction of RNA expression.
Chromatin immunoprecipitation assay
Cells were grown in 10-cm dishes to 70–80% confluence, shifted to serum-free medium for 24 h and then treated with vehicle (−) or 100 μM LA for 4 h. Thereafter, cells were cross-linked with 1% formaldehyde and sonicated. Supernatants were immunocleared with salmon DNA/protein A-agarose (Upstate Biotechnology, Inc., Lake Placid, NY, USA) and immunoprecipitated with anti c-fos (H-125) antibody or non-specific IgG (Santa Cruz Biotechnology, DBA, Milan, Italy). Pellets were washed, eluted with a buffer consisting of 1% SDS and 0.1 mol/l NaHCO3, and digested with proteinase K. DNA was obtained by phenol/chloroform extraction and precipitated with ethanol. A 4 μl volume of each sample was used as template to amplify an AP1-containing region located in the p21Cip1/WAF1 promoter by real-time PCR. The primers used were 5′- TCAGCTGCATTGGGTAAATCCT-3′ (forward) and 5′- CTGGACACATTTCCCCACGAA-3′ (reverse). Data were normalized to the input for the immunoprecipitation.
Western blot analysis
Cells were grown in 10-cm dishes, exposed to ligands, and then lysed as previously described.57 Equal amounts of whole-protein extract were resolved on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham Biosciences, Sigma-Adrich, Milan, Italy), which were probed with primary antibodies against pEGFR Tyr 1173, EGFR (1005), phosphorylated ERK1/2 (E-4), ERK2 (C-14), p-c-Jun S73, c-Jun (N), c-fos (E8), p53 (DO-1), p21 (H164) and β-actin (C2) (Santa Cruz Biotechnology) and then revealed using the chemiluminescent substrate for western blotting Westar Nova 2.0 (Cyanagen, Biogenerica, Catania, Italy).
The non-fluorescent DCFDA probe, which becomes highly fluorescent on reaction with ROS, was used to evaluate intracellular ROS production. In brief, cells (2×105) were incubated with 10 μM DCFDA (Sigma-Aldrich) at 37 °C for 30 min, washed with PBS and then exposed to treatments, as indicated. Cells were washed with PBS and the fluorescent intensity of DCF was measured (excitation at 485 nm and emission at 530 nm).
Cells were washed twice with PBS, fixed in 4% paraformaldehyde in PBS for 10 min, washed briefly with PBS, then incubated with Phalloidin-Fluorescent Conjugate (Santa Cruz Biotechnology) and visualized with the Olympus BX41 microscope and the images were taken with CSV1.14 software using a CAM XC-30 for images acquisition (Olympus Europa, Hamburg, Germany).
Cell apoptosis was determined by TUNEL assay, conducted using DeadEnd Fluorometric TUNEL System (Promega) and performed according to the manufacturer’s instructions. In brief, cells were treated for 18 h, as indicated, then were fixed in freshly prepared 4% paraformaldehyde solution in PBS (pH 7.4) for 25 min at 4 °C. After fixation, cells were permeabilized in 0.2% Triton X-100 solution in PBS for 5 min. After washing twice with washing buffer for 5 min, the cells were covered with equilibration buffer at room temperature for 5–10 min. The labeling reaction was performed using terminal deoxynucleotidyl transferase end-labeling TdT and fluorescein-dUTP cocktail for each sample and incubated for 1 h at 37 °C where TdT catalyses the binding of fluorescein-dUTP to free 3’OH ends in the nicked DNA. After rinsing, cells were washed with 2× SSC solution buffer and subsequently incubated with propidium iodide (Sigma-Aldrich) to stain nuclei and analyzed using the Cytation 3 Cell Imaging Multimode Reader (BioTek, Winooski, VT, USA).
Statistical analysis was done using ANOVA followed by Newman–Keuls’ testing to determine differences in means. P<0.05 was considered as statistically significant.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This work was supported by Associazione Italiana per la Ricerca sul Cancro (IG 16719 to MM; IG 19242 to AB).
About this article
In vitro antioxidant and antiproliferative effect of the extracts of Ephedra chilensis K Presl aerial parts
BMC Complementary and Alternative Medicine (2019)